Slide 1: Q4 & FY 2024 Results Call
Q4 & FY 2024 RESULTS CALL February 13, 2025
Slide 2: Disclaimer
iY Cellebrite DISCLAIMER This presentation has been prepared by Cellebrite DI Ltd. [the “Company’! solely for informational purposes. It is not, and should not be assumed to be, complete. This presentation is not an offer to sell securities, nor is ita solicitation of an offer to buy securities, Thi
Slide 3: Agenda
Cellebrite Q4 & FY24 AG E N DA February 13, 2025 °
Slide 4: Q4 & FY24 Results Highlights
2 Cellebrite 06 & FY24 RESU LTS HIGHLIGHTS Rule of X > $109M +17% Total Revenue - Q4 24 50 > $95M +21% , Subscription Revenue - Q4 24 : > $396M +25% y ARR - DEC 24 ar > $29M 26% Adj. EBITDA & Adj. EBITDA %* - Q4 24 TTM 12/23 TTM 12/24 MARR Growth © Adj. EBITDA Margin *Non-GAAP February 13, 2025 Note
Slide 5: Key Developments
iF Cellebrite as arv24 2025 KEY DEVELOPMENTS 77 Cellebrite FA EXECUTIVE ADVISORY User Summit 2025 February 13, 2025 °
Slide 6: 2025 Strategic Priorities
2 Cellebrite 0% & FY26 2025 STRATEGIC PRIORITIES ELEVATE THE PRODUCTS TECHNOLOGY CUSTOMERS CUSTOMER EXPERIENCE + Processes * Inseyets * Cloud + US Federal . . . + Systems * Guardian & Pathfinder - Al * Private Sector + People INVEST IN OUR PEOPLE TO ATTRACT & RETAIN THE INDUSTRY ST & BRIGHTEST Febru
Slide 7: Outlook & Summary
2 Cellebrite 04 & FY24 OUTLOOK & SUMMARY + We remain positioned as the market leader in an important segment with sustained macro tailwinds + Our outlook for the coming year reinforces our conviction that linking our technology with the brave professionals dedicated to justice is the clear path forw
Slide 8: Q4 & FY24 Financial Results
i Cellebrite 04 &FY24 ) cy | a
Slide 9: ARR Growth
2° Cellebrite 06 & FY24 A R R G R OWT H ($ in millions) $395.9 + Dec-24 ARR grew 25% $315.7 + Gross revenue retention ~92% + Existing customer expansion fuels most of the ARR growth + New logos contribute <2 percentage points to ARR expansion Dec-23 Dec-24 ™23-Dec mlinseyets mPathfinder & Guardian F
Slide 10: 2024 ARR Expansion and Q4 Wins
2 Cellebrite 04 & FY24 $104M (Net New ARR] Pathfinder & Guardian Inseyets February 13, 2025 2024 ARR EXPANSION | Q4 WINS Goal: technology to integrated workflow from DFU to IU Regional Police Deployed entire C2C platform: Inseyets with unlimited unlock module plus Department Guardian and Pathfinder
Slide 11: Revenue Growth Driven by Subscription
“vane REVENUE GROWTH DRIVEN BY SUBSCRIPTION 17% Total revenue growth 21% Total subscription revenue growth Q123° Q223) -Q323) 423 Q124 Q224 =Q324 = =—Q4 24 Q4 23 Q4 24 Hi otal subscription Wlother non-recurring* Hl Professional services Note: Numbers may not total 100% due to rounding. Note: Numbers
Slide 12: Quarterly revenue by type
$17.0 $15.6 $14.9 $14.4 $65.1 $12.6 $12.4 $12.8 $60.9 $60.3 $62.5 $12.0 $53.6 $54.7 $57.6 $52.5
Slide 13: Adjusted EBITDA & Cash Position
Adjusted EBITDA (Non-GAAP, $M) and Adjusted EBITDA Margin (Non-GAAP, %] 29% 26% $28.8) 24% 25% $22.7] om $20.8} 20% $17.6 15% 10% Q1 23 Q2 23 Q3 23 Q423 QI 24 Q2 24 Q3 24 Q4 24 Coleone mana ADJUSTED EBITDA & CASH POSITION Cash Position $483.8M (12/31/24) +$70.2M from Q3 24 | +$152.0 from Q4 23 Cash
Slide 14: Financial Forecast
2° Cellebrite 04 & FY24 ARR ARR Growth [y/y) Revenue Revenue Growth (y/y] Adjusted EBITDA* Adjusted EBITDA Margin* February 13, 2025 * Non-GAAP. 2024A $396M +25% $401M +23% $99.4M 24.8% FINANCIAL FORECAST Q1 ‘25 EXPECTATIONS FY ‘25 EXPECTATIONS (AS OF 02/13/25) (AS OF 02/13/25) $406M - $411M $480 -
Slide 15: Appendix
i Cellebrite 04 &FY24 ? ° P gilt : o\4 TTT LE Ee : eee igffeiae ° : * . aay . 2 er8", fe e fig dtaty; ise: : VARS SRS e e . Wt ee . e a : . is i Y suceseee re oe . M4 ° * of ty . ‘ : .Y : 2° . F i riité FERAL LSA RRR oe, pbeteersee setts ev ~~ 6 . +s >> i. i.e ef . “\\ - * fo _* . » &
Slide 16: i Cellebrite &FY24
i Cellebrite 04 &FY24 ? ° P gilt : o\4 TTT LE Ee : eee igffeiae ° : * . aay . 2 er8", fe e fig dtaty; ise: : VARS SRS e e . Wt ee . e a : . is i Y suceseee re oe . M4 ° * of ty . ‘ : .Y : 2° . F i riité FERAL LSA RRR oe, pbeteersee setts ev ~~ 6 . +s >> i. i.e ef . “\\ - * fo _* . » &
Slide 17: Summary financial data
For the three months ended For the year ended December 31, December 31, 2024 2023 2024 2023 Revenue 109,049 93,013 401,203 325,110 Gross profit 91,425 78,097 338,610 271,879 Gross margin 83.8% 84.0% 84.4% 83.6% Operating income 15,727 14,999 56,906 33,237 Operating margin 14.4% 16.1 % 14.2% 10.2 % N
Slide 18: Cost of revenue and gross profit reconciliation
December 31, December 31, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Cost of revenue $ 17,624 $ 14,916 $ 62,593 $ 53,231 Less: Share-based compensation 575 498 2,227 1,733 Acquisition-related costs — 13 2 52 Non-GAAP cost of revenue $ 17,049 $ 14,405 $ 60,364 $ 51,446 For th
Slide 19: Operating expenses and operating income reconciliation
For the three months ended For the year ended December 31, December 31, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Operating expenses $ 75,698 $ 63,098 $ 281,704 $ 238,642 Less: Issuance expenses — — — (345) Share-based compensation 8,694 4,562 28,348 17,265 Amortization of
Slide 20: Net income reconciliation
For the three months ended For the year ended December 31, December 31, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net income (loss) $ 19,269 $ (14,647) $ (283,007) $ (81,100) Issuance expenses — — — (345) Share-based compensation 9,269 5,060 30,575 18,998 Amortization of in
Slide 21: Adjusted EBITDA reconciliation
Cellebrite DI Ltd. Reconciliation of GAAP to Non-GAAP Financial Information (U.S Dollars in thousands, except share and per share data) For the three months ended For the year ended December 31, December 31, 2024 2023 2024 2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net income (loss) $ 19,2
Slide 22: Appendix: Definitions
2 Cellebrite APPENDIX DEFINITIONS 1. Annual Recurring Revenue: Annual recurring revenue (ARR) is defined as the annualized value of active term-based subscription license contracts and maintenance contracts related to perpetual licenses in effect at the end of that period. Subscription license contr
Slide 23: Thank You
Cellebrite Q4 & FY24 THANK YOU February 13, 2025